Uptake of non-statin lipid-lowering therapies for secondary prevention in community practice

Corey K. Bradley; Ahmed A. Kolkailah; Nishant P. Shah; Courtney B. Page; Eric D. Peterson; Ann Marie Navar

doi:10.1016/j.jacl.2023.03.006

Uptake of non-statin lipid-lowering therapies for secondary prevention in community practice

Corey K. Bradley, Ahmed A. Kolkailah, Nishant P. Shah, Courtney B. Page, Eric D. Peterson, Ann Marie Navar

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Nearly two-thirds of individuals with atherosclerotic cardiovascular disease (ASCVD) do not reach target low-density lipoprotein cholesterol despite statin therapy. Three novel lipid-lowering therapies have proven to further reduce ASCVD beyond statins, including: ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), and icosapent ethyl. This study evaluated the use of these three agents in 728,423 individuals with ASCVD from 89 US health systems from 01/2018 through 03/2021 using the electronic health record. As of 2021, only 6.0% of ASCVD patients were on ezetimibe, 1.6% were on a PCSK9i, and 1.3% on icosapent ethyl, with utilization only marginally increasing over the study period. Addressing the underutilization of non-statin lipid-lowering therapy for secondary prevention is a critical step in improving the treatment gap of patients with residual risk of ASCVD.

Original language	English (US)
Pages (from-to)	412-414
Number of pages	3
Journal	Journal of Clinical Lipidology
Volume	17
Issue number	3
DOIs	https://doi.org/10.1016/j.jacl.2023.03.006
State	Published - May 1 2023

Keywords

Anticholesterolemic agents
Atherosclerosis
Cardiovascular disease
LDL
Lipid
Secondary prevention

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Nutrition and Dietetics
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacl.2023.03.006

Cite this

@article{988fb94c35244eec8360c5dcbe25831e,

title = "Uptake of non-statin lipid-lowering therapies for secondary prevention in community practice",

abstract = "Nearly two-thirds of individuals with atherosclerotic cardiovascular disease (ASCVD) do not reach target low-density lipoprotein cholesterol despite statin therapy. Three novel lipid-lowering therapies have proven to further reduce ASCVD beyond statins, including: ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), and icosapent ethyl. This study evaluated the use of these three agents in 728,423 individuals with ASCVD from 89 US health systems from 01/2018 through 03/2021 using the electronic health record. As of 2021, only 6.0% of ASCVD patients were on ezetimibe, 1.6% were on a PCSK9i, and 1.3% on icosapent ethyl, with utilization only marginally increasing over the study period. Addressing the underutilization of non-statin lipid-lowering therapy for secondary prevention is a critical step in improving the treatment gap of patients with residual risk of ASCVD.",

keywords = "Anticholesterolemic agents, Atherosclerosis, Cardiovascular disease, LDL, Lipid, Secondary prevention",

author = "Bradley, {Corey K.} and Kolkailah, {Ahmed A.} and Shah, {Nishant P.} and Page, {Courtney B.} and Peterson, {Eric D.} and Navar, {Ann Marie}",

note = "Funding Information: Funding: This project was supported by grant funding to Duke University and UT Southwestern Medical Center from Janssen. The sponsor had no role in the development of the analytic plan, data analysis, data interpretation, or decision to publish. Publisher Copyright: {\textcopyright} 2023",

year = "2023",

month = may,

day = "1",

doi = "10.1016/j.jacl.2023.03.006",

language = "English (US)",

volume = "17",

pages = "412--414",

journal = "Journal of Clinical Lipidology",

issn = "1933-2874",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - Uptake of non-statin lipid-lowering therapies for secondary prevention in community practice

AU - Bradley, Corey K.

AU - Kolkailah, Ahmed A.

AU - Shah, Nishant P.

AU - Page, Courtney B.

AU - Peterson, Eric D.

AU - Navar, Ann Marie

N1 - Funding Information: Funding: This project was supported by grant funding to Duke University and UT Southwestern Medical Center from Janssen. The sponsor had no role in the development of the analytic plan, data analysis, data interpretation, or decision to publish. Publisher Copyright: © 2023

PY - 2023/5/1

Y1 - 2023/5/1

N2 - Nearly two-thirds of individuals with atherosclerotic cardiovascular disease (ASCVD) do not reach target low-density lipoprotein cholesterol despite statin therapy. Three novel lipid-lowering therapies have proven to further reduce ASCVD beyond statins, including: ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), and icosapent ethyl. This study evaluated the use of these three agents in 728,423 individuals with ASCVD from 89 US health systems from 01/2018 through 03/2021 using the electronic health record. As of 2021, only 6.0% of ASCVD patients were on ezetimibe, 1.6% were on a PCSK9i, and 1.3% on icosapent ethyl, with utilization only marginally increasing over the study period. Addressing the underutilization of non-statin lipid-lowering therapy for secondary prevention is a critical step in improving the treatment gap of patients with residual risk of ASCVD.

AB - Nearly two-thirds of individuals with atherosclerotic cardiovascular disease (ASCVD) do not reach target low-density lipoprotein cholesterol despite statin therapy. Three novel lipid-lowering therapies have proven to further reduce ASCVD beyond statins, including: ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), and icosapent ethyl. This study evaluated the use of these three agents in 728,423 individuals with ASCVD from 89 US health systems from 01/2018 through 03/2021 using the electronic health record. As of 2021, only 6.0% of ASCVD patients were on ezetimibe, 1.6% were on a PCSK9i, and 1.3% on icosapent ethyl, with utilization only marginally increasing over the study period. Addressing the underutilization of non-statin lipid-lowering therapy for secondary prevention is a critical step in improving the treatment gap of patients with residual risk of ASCVD.

KW - Anticholesterolemic agents

KW - Atherosclerosis

KW - Cardiovascular disease

KW - LDL

KW - Lipid

KW - Secondary prevention

UR - http://www.scopus.com/inward/record.url?scp=85151515565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85151515565&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2023.03.006

DO - 10.1016/j.jacl.2023.03.006

M3 - Article

C2 - 37029056

AN - SCOPUS:85151515565

SN - 1933-2874

VL - 17

SP - 412

EP - 414

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

IS - 3

ER -

Uptake of non-statin lipid-lowering therapies for secondary prevention in community practice

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this